Cancer Insight is a Texas-based boutique contract research organization (CRO) dedicated to discovering, developing and testing emerging biotechnologies focused on cancer immunotherapy. Founded by industry pioneer Dr.
Principal Investigator(s)
George Peoples
Funded by
Industry Sponsored
The purpose of this study is to (1) produce and test a vaccine that is made from a patient’s tumor cells and white blood cells to determine if it can prevent melanoma recurrence; (2) to look at the safety of the vaccine (what side effects it has); and (3) to look at the immune system’s response to this vaccine.
Cancer Insight is a Texas-based boutique contract research organization (CRO) dedicated to discovering, developing and testing emerging biotechnologies focused on cancer immunotherapy. Founded by industry pioneer Dr.
Principal Investigator(s)
George Peoples
Funded by
Industry Sponsored
The goal of this trial is to compare if and for how long trastuzumab combined with either NeuVax (nelipepimut-S given with GM-CSF [sargramostim]) or sargramostim can help control the disease in patients with HER2 positive breast cancer. NeuVax is not FDA approved or commercially available. It is currently being used for research purposes only. Sargramostim is FDA approved and commercially available to help raise patients’ white blood cell counts after chemotherapy. Giving NeuVax or sargramostim to patients with HER2-positive breast cancer is investigational.
Cancer Insight is a Texas-based boutique contract research organization (CRO) dedicated to discovering, developing and testing emerging biotechnologies focused on cancer immunotherapy. Founded by industry pioneer Dr.
Principal Investigator(s)
George Peoples
Funded by
Industry Sponsored
The goal of this clinical research study is to learn the most effective way to give patients a vaccine in order for the immune system to react against folate binding protein (FBP) and FBP-containing cancers. The E39 and J65 peptide (a piece of a protein) vaccines are designed to cause the immune system to attack certain cancer cells (those with FBP), which may help lower the risk that the cancer will come back.
Cancer Insight is a Texas-based boutique contract research organization (CRO) dedicated to discovering, developing and testing emerging biotechnologies focused on cancer immunotherapy. Founded by industry pioneer Dr.
Principal Investigator(s)
George Peoples
Funded by
Industry Sponsored
This study includes patients that have been treated for node-positive (NP) or high-risk node-negative (NN) breast cancer where they are at risk for recurrence (breast cancer coming back); and also because tumor cells show a specific protein called HER2/neu on their cell surfaces. “Node-positive” means that breast cancer has been found in the lymph nodes.
Cancer Insight is a Texas-based boutique contract research organization (CRO) dedicated to discovering, developing and testing emerging biotechnologies focused on cancer immunotherapy. Founded by industry pioneer Dr.
Principal Investigator(s)
George Peoples
Funded by
Industry Sponsored
The purposes of the study are as follows: 1) to test the development of a potential anticancer study called E39 peptide vaccine and J65 peptide vaccine; 2) to determine if the study vaccine is safe; 3) to determine the best dose of the study vaccine 4) to learn more about the side effects of the study vaccine and how it affects the immune system; and 5) to determine if folate binding protein expression in tumor is associated with the effectiveness of the vaccine.
